^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    Cyramza (ramucirumab) (VEGFR-2 inhibitor) +
    evorpacept (ALX148) (CD47 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO-GI 2021
    Title:

    SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer

    Published date:
    07/04/2021
    Excerpt:
    ...patients with second-line or greater HER2-positive G/GEJ cancer…received ALX148 (10 or 15 mg/kg QW) in combination with trastuzumab, ramucirumab, and paclitaxel…Of these patients, 15 were evaluable for objective response and demonstrated an objective response rate (ORR) of 73.3%...
    Secondary therapy:
    paclitaxel
    DOI:
    10.1016/j.annonc.2021.05.055
    Trial ID:
    ASPEN-01
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Immunother Cancer
    Title:

    ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)

    Published date:
    11/04/2020
    Excerpt:
    Pts with previously treated advanced HER2-positive GC...received ALX148 (A)...in combination with trastuzumab (T) + ramucirumab (ram) + paclitaxel (pac)... Twelve patients with ≥2L GC received A+T+ram+pac and were evaluated for safety….Nine of the 12 patients were response-evaluable and reported a 66% ORR with 6PR and 3SD (including one ongoing near PR, ↓29.6%).
    Secondary therapy:
    paclitaxel
    DOI:
    10.1136/jitc-2020-SITC2020.0404